Background

Celiac disease (CeD), a gastrointestinal disorder, and rheumatoid arthritis (RA), a chronic joint disease, have long been classified as distinct entities with different target organs and clinical manifestations. The former is characterized by small intestinal villous injury triggered by gluten ingestion, while the latter primarily involves synovial inflammation and bone erosion. Despite the clinical disconnect, immunogenetic researchers have long noted a peculiar similarity between the two diseases. In both conditions, human leukocyte antigen class II (HLA-II) genes act as the primary genetic factor determining susceptibility to onset. It was also confirmed that autoantibodies targeting post-translational modification (PTM) products of intracellular proteins are abundantly detected in serum.

Until now, the academic community has investigated each disease separately, focusing on the discovery of specific mutant antigens and autoantibodies. In CeD, the process by which tissue transglutaminase 2 (TG2) deamidates gluten peptides has been elucidated, and in RA, the mechanism by which peptidyl arginine deiminase (PAD) citrullinates proteins has been established. However, it remains unclear why autoantibodies targeting the enzyme itself and those targeting modified substrate peptides are simultaneously produced in large quantities, and how physical interactions between the modified enzyme and its substrate lead to a breakdown of immune tolerance. This was because the classical clonal selection hypothesis presented in immunology textbooks alone made it difficult to fully explain the combined pathway of enzyme reactions and T cell co-stimulation signals.

Key Findings

Researchers led by Professor Ludvig M. Sollid of the University of Oslo, publishing in the latest issue of PNAS, have unified these two diseases into a single pathogenic model. The study demonstrated that the molecular pathway where an enzyme-substrate complex is captured and processed by B cells is the core mechanism triggering autoimmunity in both CeD and RA.

In CeD, anti-TG2 B cells recognize the modifying enzyme TG2 via the surface B-cell receptor (BCR). If TG2 is bound to a gluten peptide forming a complex, the B cell internalizes both the enzyme and the foreign peptide through receptor-mediated endocytosis. After the complex is degraded into peptide units within the cell's lysosomes, B cells present deamidated gluten fragments on their HLA-DQ2 or HLA-DQ8 molecules. Modified gluten-specific CD4+ T cells recognize this complex and provide survival and proliferation signals to the B cells. This cooperative mechanism drives the massive production of anti-TG2 autoantibodies.

The researchers demonstrated that the same pattern holds true in the joint synovium of RA patients. In patients positive for the HLA-DRB1 shared epitope, PAD2 and PAD4 are autoantigen targets. Anti-PAD B cells internalize PAD complexes bound to joint structural proteins via their BCRs. The processed citrullinated peptides are then presented on the cell surface via HLA-DR molecules. Subsequently, citrullinated protein-reactive CD4+ T cells provide activation signals to helper T cells, thereby simultaneously amplifying the production of both anti-PAD antibodies and anti-citrullinated protein antibodies (ACPA). The study reveals that while B cells capture enzymes in both diseases, the central axis of pathogenesis is a 'hapten-carrier-like linkage' where the antigen presented to T cells is the substrate peptide chemically modified by the enzyme.

Significance and Outlook

This finding suggests that autoimmune diseases occurring in anatomically distinct tissues share the same intracellular uptake pathway involving enzyme-substrate complexes. This re-evaluates the pathological role of B cells as antigen-presenting cells and provides a universal analytical framework for studying other autoimmune diseases related to misfolded proteins beyond rheumatoid arthritis.

In terms of therapeutic strategy, this heralds a paradigm shift. Instead of conventional immunosuppressants or broad antibody depletion, small molecule compounds or complex-formation inhibitors that block the binding of specific modifying enzymes and substrates have emerged as precision therapeutic targets. It also becomes possible to design targeted therapies that selectively inactivate only the enzyme-binding sites on B cells.

However, it remains a challenge to determine whether the molecular mechanisms elucidated at the laboratory level perfectly align with disease dynamics across different stages in the human body. Further longitudinal clinical studies are needed to determine when PAD enzyme complexes are first exposed to the immune system in extra-articular tissues, such as the lungs or periodontal tissue, during the early stages of RA. Research must also ensure a safety window so that drugs inhibiting complex binding do not interfere with the enzyme's original physiological functions.